Improving the efficiency of clinical trials in multiple sclerosis

BACKGROUND: Phase 3 clinical trials for disease-modifying therapies in relapsing-remitting multiple sclerosis (RRMS) have utilized a limited number of conventional designs with a high degree of success. However, these designs limit the types of questions that can be addressed, and the time and cost...

Descripción completa

Detalles Bibliográficos
Autores principales: Marrie, Ruth Ann, Sormani, Maria Pia, Apap Mangion, Sean, Bovis, Francesca, Cheung, Winson Y, Cutter, Gary R, Feys, Peter, Hill, Michael D, Koch, Marcus Werner, McCreary, Morgan, Mowry, Ellen M, Park, Jay JH, Piehl, Fredrik, Salter, Amber, Chataway, Jeremy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Meeting Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10413792/
https://www.ncbi.nlm.nih.gov/pubmed/37555492
http://dx.doi.org/10.1177/13524585231189671

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10413792/
https://www.ncbi.nlm.nih.gov/pubmed/37555492
http://dx.doi.org/10.1177/13524585231189671

Ejemplares similares